Mala Rakoto-Andrianarivelo
Biographic Data
| ID | 9020618 |
|---|---|
| NAME | Mala Rakoto-Andrianarivelo |
| GIVEN NAMES | Mala |
| FAMILY NAME | Rakoto-Andrianarivelo |
| SIGNATURE | RAKOTO-ANDRIANARIVELO M |
| AFFILIATIONS | Centre d'Infectiologie, Charles Mérieux, Antanarivo, Madagascar |
| VERIFIED | No |
| TOTAL WORKS | 5 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 5 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Development and validation of a novel clinical risk score to predict hypoxaemia in children with pneumonia using the WHO PREPARE dataset
BACKGROUND: Hypoxaemia predicts mortality at all levels of care, and appropriate management can reduce preventable deaths. However, pulse oximetry and oxygen therapy remain inaccessible in many primary care health facilities. We aimed to develop and validate a simple risk score comprising commonly evaluated clinical features to predict hypoxaemia in 2-59-month-old children with pneumonia. METHODS: Data from seven studies conducted in five countri…
Large-scale field application of a fingerstick blood test for Mycobacterium leprae infection
Since 2018, the WHO recommends provision of single-dose rifampicin post-exposure prophylaxis (SDR-PEP) to contacts of leprosy patients. In the Post-ExpOsure Prophylaxis for LEprosy (PEOPLE) trial that took place in the Comoros (Anjouan and Mohéli) and Madagascar (2019–2023), single double-dose rifampicin (SDDR)-PEP administration modalities were compared. Additionally, in 16/64 villages, anti- M. leprae phenolic glycolipid-I (anti-PGL-I) IgM leve…
Derivation and validation of a novel risk assessment tool to identify children aged 2–59 months at risk of hospitalised pneumonia-related mortality in 20 countries
INTRODUCTION: Existing risk assessment tools to identify children at risk of hospitalised pneumonia-related mortality have shown suboptimal discriminatory value during external validation. Our objective was to derive and validate a novel risk assessment tool to identify children aged 2-59 months at risk of hospitalised pneumonia-related mortality across various settings. METHODS: We used primary, baseline, patient-level data from 11 studies, incl…
Assembling a global database of child pneumonia studies to inform WHO pneumonia management algorithm
Background: The existing World Health Organization (WHO) pneumonia case management guidelines rely on clinical symptoms and signs for identifying, classifying, and treating pneumonia in children up to 5 years old. We aimed to collate an individual patient-level data set from large, high-quality pre-existing studies on pneumonia in children to identify a set of signs and symptoms with greater validity in the diagnosis, prognosis, and possible trea…
External validation of the Risc, Risc-Malawi, and PERCH clinical prediction rules to identify risk of death in children hospitalized with pneumonia
BACKGROUND: Existing scores to identify children at risk of hospitalized pneumonia-related mortality lack broad external validation. Our objective was to externally validate three such risk scores. METHODS: We applied the Respiratory Index of Severity in Children (RISC) for HIV-negative children, the RISC-Malawi, and the Pneumonia Etiology Research for Child Health (PERCH) scores to hospitalized children in the Pneumonia REsearch Partnerships to …
No prominent works on this page.
External validation of the Risc, Risc-Malawi, and PERCH clinical prediction rules to identify risk of death in children hospitalized with pneumonia
BACKGROUND: Existing scores to identify children at risk of hospitalized pneumonia-related mortality lack broad external validation. Our objective was to externally validate three such risk scores. METHODS: We applied the Respiratory Index of Severity in Children (RISC) for HIV-negative children, the RISC-Malawi, and the Pneumonia Etiology Research for Child Health (PERCH) scores to hospitalized children in the Pneumonia REsearch Partnerships to …
Derivation and validation of a novel risk assessment tool to identify children aged 2–59 months at risk of hospitalised pneumonia-related mortality in 20 countries
INTRODUCTION: Existing risk assessment tools to identify children at risk of hospitalised pneumonia-related mortality have shown suboptimal discriminatory value during external validation. Our objective was to derive and validate a novel risk assessment tool to identify children aged 2-59 months at risk of hospitalised pneumonia-related mortality across various settings. METHODS: We used primary, baseline, patient-level data from 11 studies, incl…
Assembling a global database of child pneumonia studies to inform WHO pneumonia management algorithm
Background: The existing World Health Organization (WHO) pneumonia case management guidelines rely on clinical symptoms and signs for identifying, classifying, and treating pneumonia in children up to 5 years old. We aimed to collate an individual patient-level data set from large, high-quality pre-existing studies on pneumonia in children to identify a set of signs and symptoms with greater validity in the diagnosis, prognosis, and possible trea…
Development and validation of a novel clinical risk score to predict hypoxaemia in children with pneumonia using the WHO PREPARE dataset
BACKGROUND: Hypoxaemia predicts mortality at all levels of care, and appropriate management can reduce preventable deaths. However, pulse oximetry and oxygen therapy remain inaccessible in many primary care health facilities. We aimed to develop and validate a simple risk score comprising commonly evaluated clinical features to predict hypoxaemia in 2-59-month-old children with pneumonia. METHODS: Data from seven studies conducted in five countri…
Large-scale field application of a fingerstick blood test for Mycobacterium leprae infection
Since 2018, the WHO recommends provision of single-dose rifampicin post-exposure prophylaxis (SDR-PEP) to contacts of leprosy patients. In the Post-ExpOsure Prophylaxis for LEprosy (PEOPLE) trial that took place in the Comoros (Anjouan and Mohéli) and Madagascar (2019–2023), single double-dose rifampicin (SDDR)-PEP administration modalities were compared. Additionally, in 16/64 villages, anti- M. leprae phenolic glycolipid-I (anti-PGL-I) IgM leve…
Intensive care medicine (4 works) · Internal Medicine (4 works) · Medicine (4 works) · Pneumonia (4 works) · Pneumonia and Respiratory Infections (4 works) · Pediatrics (3 works) · Advanced Causal Inference Techniques (2 works) · Emergency Medicine (2 works) · Logistic regression (2 works) · Respiratory viral infections research (2 works)